Background and Objective: Imatinib mesylate is the first effective therapy for advanced unresectable gastrointestinal stromal tumours (GIST). Adoption of this therapy in clinical practice is ...

Oxazepam capsule: The 10- and 15-milligram oxazepam capsules are in shortage, with an expected recovery date of Dec. 27, 2024. This medication, used for anxiety disorders, is experiencing ...

Imatinib mesylate has anti-inflammatory properties, because it is a specific and potent inhibitor of several protein tyrosine kinases. Paniagua et al. have investigated imatinib's mechanism of ...

The US Food and Drug Administration (FDA) has approved Shorla Oncology’s Imkeldi oral solution to treat certain forms of ...

"Shorla Oncology’s IMKELDI approved by FDA for leukaemia cancers" was originally created and published by Pharmaceutical ...

Imatinib mesylate is a tyrosine kinase inhibitor used in the treatment of cancers including chronic myeloid leukemia. In their study, however, Kerkelä et al. report that this drug can be ...

Imatinib (Imkeldi) is the first oral liquid TKI approved for multiple cancers, enhancing treatment accessibility and dosing precision. The drug is effective as a first-line treatment, especially ...

Inhibikase’s cardiopulmonary disease portfolio is led by IkT-001Pro, a prodrug of imatinib mesylate, for Pulmonary Arterial Hypertension that will deliver imatinib in a form that the Company ...